Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation

       Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation

PR Newswire

BETHESDA, Md., March 13, 2013

BETHESDA, Md., March 13, 2013 /PRNewswire-USNewswire/ --The American
Gastroenterological Association (AGA) Research Foundation is pleased to
welcome Salix Pharmaceuticals as a supporter of the foundation's endowment.

The AGA Research Foundation provides research funding grants to young
investigators in gastroenterology and hepatology. The foundation's grants
transform young researchers' lives by encouraging them to embark on and
continue careers in research. Many ultimately make discoveries that improve
patient care.

Salix Pharmaceuticals is a specialty pharmaceutical company committed to the
prevention and treatment of gastrointestinal (GI) disorders.

"AGA is committed to helping young scientists investigate the GI and liver
diseases that plague millions of people. AGA-funded researchers hold the keys
to the patient care advances of tomorrow. AGA is thrilled that Salix
recognizes the importance of supporting discovery and has made a significant
commitment to the AGA Research Foundation for years to come," said Nicholas F.
LaRusso, MD, AGAF, chair of the AGA Research Foundation.

Salix Pharmaceuticals' $1.125 million, five-year commitment to the AGA
Research Foundation endowment will help ensure that researchers have the tools
they need to discover ways to better diagnose, treat and cure digestive
diseases.

"Salix is passionate about providing solutions to address unmet treatment
needs for people with GI disorders," said Carolyn Logan, president and chief
executive officer, Salix Pharmaceuticals. "We are pleased to support the AGA
Research Foundation in its mission of the advancement of gastroenterological
and hepatological research."

Many breakthroughs have been achieved through gastroenterological and
hepatological research over the past century, forming the basis of the modern
medical practice. The AGA Research Foundation is working to continue this
tradition of discovery and ultimately improve the lives of patients with
digestive diseases through the researchers it funds. Salix's support of the
AGA Research Foundation's mission is a critical investment in the future of
the field of gastroenterology.

About the AGA Research Foundation
The AGA Research Foundation is the foundation of the American
Gastroenterological Association (AGA), the leading professional society
representing gastroenterologists and hepatologists worldwide. The mission of
the foundation is to raise funds to support young researchers in
gastroenterology and hepatology. The AGA Research Foundation awards nearly
$1.2 million in research grants annually. www.gastro.org/foundation

About Salix Pharmaceuticals
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina,
develops and markets prescription pharmaceutical products for the prevention
and treatment of gastrointestinal diseases. Salix's strategy is to in-license
late-stage or marketed proprietary therapeutic products, complete any required
development and regulatory submission of these products, and market them
through the Company's gastroenterology specialty sales and marketing team.

Salix markets XIFAXAN® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP® (PEG
3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate
and Ascorbic Acid for Oral Solution), OSMOPREP® (sodium phosphate monobasic
monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO®
(mesalamine) extended-release capsules 0.375 g, GIAZO™ (balsalazide disodium)
tablets, COLAZAL® (balsalazide disodium) Capsule, METOZOLV® ODT
(metoclopramide HCl), RELISTOR® (methylnaltrexone bromide) Subcutaneous
Injection, FULYZAQ™ (crofelemer) delayed-release tablets, SOLESTA®, DEFLUX®,
PEPCID® (famotidine) for Oral Suspension, DIURIL® (Chlorothiazide) Oral
Suspension, AZASAN® (Azathioprine) Tablets, USP, 75/100 mg, ANUSOL-HC® 2.5%
(Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone
Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT®
Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Budesonide
foam, RELISTOR® , LUMACAN™ and rifaximin for additional indications are under
development.

For full prescribing information and important safety information on Salix
products, including BOXED WARNINGS for OSMOPREP, AZASAN and METOZOLV, please
visit www.salix.com where the Company promptly posts press releases, SEC
filings and other important information or contact the Company at 919
862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol
"SLXP".

For more information, please visit our Website at www.salix.com or contact the
Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook
(www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page
and web site is not incorporated in our SEC filings.

Many breakthroughs have been achieved through gastroenterological and
hepatological research over the past century, forming the basis of the modern
medical practice. The AGA Research Foundation is working to continue this
tradition of discovery and ultimately improve the lives of patients with
digestive diseases through the researchers it funds. Salix's support of the
AGA Research Foundation's mission is a critical investment in the future of
the field of gastroenterology.

SOURCE American Gastroenterological Association

Website: http://www.gastro.org
Website: http://www.salix.com
Contact: Aimee Frank (AGA), +1-301-941-2625, media@gastro.org
 
Press spacebar to pause and continue. Press esc to stop.